BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease PipelineMarketBeat • Thursday
BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptSeeking Alpha • Thursday
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/03/26
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry DiseasePRNewsWire • 10/29/26
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ETPRNewsWire • 10/26/26
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 10/19/26
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockZacks Investment Research • 10/13/26
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual MeetingPRNewsWire • 10/09/26
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual CongressPRNewsWire • 10/02/26
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of DirectorsPRNewsWire • 09/14/26
BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/10/26